Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Aug 6, 2015

Harmonyx Test for Pain

Genetic testing company Harmonyx recently launched the Harmonyx Test for Pain, a $99 assay designed to provide personalized guidance to patients taking medicine for chronic or acute pain. The test uses a patient swab taken at a Harmonyx partner pharmacy, and examines the effects of eight genes on a patient's metabolism and efficacy of more than 20 pain mediciations, ranging from common over-the-counter drugs like ibuprofen and naproxen to frequently prescribed medications like morphine, methadone, hydrocodone, codeine, and oxycodone. Harmonyx provides a state-licensed physician to review each patient test request, and, if deemed medically appropriate, the test is ordered on behalf of the patient. Detailed results are returned to the pharmacist and treating physician in as little as 24 hours after the lab receives the test, Harmonyx said. Harmonyx, based in Memphis, Tennessee, is CAP accredited and CLIA certified.

Pathway Genomics Pathway Fit Genetic Test

Pathway Genomics has announced a limited time $99 pricing for the Pathway Fit genetic test. The test analyzes more than 75 genetic markers known to impact metabolism, exercise, and energy consumption use within the human body. Using this analysis, the test creates a personalized nutrigenomic profile that provides individualized information to physicians and their patients in order to help them understand how genetics and lifestyle may impact their diet nutrition and exercise, said Pathway Genomics in a statement.

Biocept KRAS Liquid Biopsy Test

Biocept has launched a new blood-based KRAS mutation test to help physicians identify patients who might benefit from currently available targeted therapies. According to the company the high sensitivity of its technology could also allow the test to be used for monitoring patients' responses to treatment and the progression of their disease during the course of therapy.

The quantitative Target Selector KRAS assay joins Biocept's existing portfolio of liquid biopsy tests for melanoma, breast, lung and gastric cancer biomarkers. The firm's platform analyzes circulating tumor DNA in circulating tumor cells and plasma.

For more recently launched products and services, please see the New Products page on our website.